<DOC>
	<DOCNO>NCT00818454</DOCNO>
	<brief_summary>The primary goal trial compare efficacy safety COMBIVENT CFC MDI albuterol HFA MDI , current standard reliever medication asthma . In first cross-over part study ( Treatment Phases 1 2 ) market product , COMBIVENT CFC MDI use . In second , parallel group part trial ( Treatment Phase 3 ) COMBIVENT RESPIMAT test acute bronchodilator efficacy blind manner clinic visit . During third 4-week treatment phase open label COMBIVENT RESPIMAT use symptom relief need .</brief_summary>
	<brief_title>4 Week 2 Way Crossover Double Blind Treatment Phase With Combivent CFC Versus Albuterol Followed 4 Week Open Label Combivent Respimat When All Drugs Are Used Symptom Relief Needed Pts With Moderate Severe Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>1 . All patient must sign date Informed Consent consistent International Conference Harmonization Good Clinical Practices ( ICH GCP ) guideline local regulation prior participation trial ( i.e. , prior study procedure , include washout medication ) Visit 1 . 2 . Male female patient great equal 18 year age . 3 . Physician diagnosis moderatetosevere asthma ( GINA Guidelines ) exist &gt; 1 year . 4 . Reversible airway obstruction ( equal 12 % least 200 mL improvement FEV1 post bronchodilator 4 puff albuterol HFA MDI ) . 5 . Prebronchodilator clinic measure FEV1 ≤80 % predict normal value ( measure great equal 6 hour last use short act bronchodilator great equal 12 hour last use LABA applicable ) . 6 . Continuous treatment inhaled corticosteroid ( ICS ) without longacting beta agonist ( LABA ) controller medication ( ) least 6 week prior screen ( GINA 2007 Treatment Steps 3 5 ) . 7 . No change do regimen ICS LABA controller medication ( include oral corticosteroid [ OCS ] applicable ) , least 2 week prior Visit 2 . 8 . Use short act bronchodilator least three time week symptom relief 2 week prior Visit 1 . 9 . Score ≥1.5 point Asthma Control Questionnaire ( ACQ ) ( see Appendix 10.6 ) . 10 . Able perform technically acceptable pulmonary function test clinic peak flow measurement eDiary/Peak Expiratory Flow Meter . 11 . Able perform necessary recording ( symptom need medication use ) electronic diary , part eDiary/Peak Expiratory Flow Meter . 12 . Investigator assessment patient ability inhale medication meter dose inhaler RESPIMAT inhaler . 1 . Significant disease asthma limit diagnosis COPD , , active tuberculosis , cystic fibrosis , alpha 1 antitrypsin deficiency , clinically significant bronchiectasis , interstitial lung disease , allergic bronchopulmonary aspergillosis , constrictive bronchiolitis . A significant disease define disease , opinion investigator , may ( ) put patient risk participation study , ( ii ) influence result study , ( iii ) cause concern regard patient ability participate study . 2 . History thoracotomy pulmonary resection . Patients history thoracotomy reason evaluate per exclusion criterion 1 . 3 . History lifethreatening asthma attack . 4 . Worsening asthma require treatment addition increase OCS dose ( steroid burst ) 4 week period prior Visit 2 . 5 . Current exsmokers quit &lt; 1 year enrollment . Exsmokers quit less 1 year enrollment must cigarette smoke history le 10 pack year . Pack year = Number cigarettes/day x year smoke 20 6 . Use oral betaadrenergic agent within 4 week prior screen . 7 . Treatment inhaled ipratropium , ipratropium/albuterol combination , nasal ipratropium within 1week Visit 2 . 8 . Treatment inhaled tiotropium within 4 week Visit 2 . 9 . Known hypersensitivity anticholinergic drug , benzalkonium chloride ( BAC ) , ethylenediaminetetracetic acid ( EDTA ) component tiotropium inhalation solution MDI . 10 . Known narrowangle glaucoma . 11 . Clinically relevant abnormal hematology blood chemistry screen abnormality defines significant disease define exclusion criterion 1 . 12 . Recent history ( i.e. , one year less ) myocardial infarction . Cardiac arrhythmia , newly diagnose arrhythmias and/or arrhythmia require intervention ( i.e. , hospitalization , cardio version , pacemaker placement , automatic implantable cardiac defibrillator placement ) change drug therapy last year . 13 . Hospitalization cardiac failure past year . 14 . Malignancy patient undergone resection , radiation therapy chemotherapy within last five year , exception treat basal cell carcinoma . 15 . Unwillingness inability use highly effective method birth control woman childbearing potential . Highly effective method birth control define result low failure rate ( i.e. , less 1 % per year ) use consistently correctly implant , injectables , combine oral contraceptive , intrauterine device ( IUDs ) , sexual abstinence vasectomise partner . Barrier method contraception accept condom occlusive cap use together spermicide ( e.g. , foam gel ) . Female patient consider childbearing potential unless surgically sterilize hysterectomy bilateral tubal ligation/salpingectomy , postmenopausal least two year . 16 . Pregnancy nursing . 17 . Any investigational drug take within 30 day six halflives ( whichever great ) prior Visit 2 . 18 . Previous randomization study current participation another study . 19 . Symptomatic prostate hypertrophy bladder neck obstruction . Patients symptomatically control prostate hypertrophy medication may include continue medication . 20 . Use monoamine oxidase inhibitor tricyclic antidepressant . Examples include limited follow monoamine oxidase inhibitor nardil , parnate , marplan tricyclic antidepressant : amitriptyline , norpramine , pamelor . 21 . History and/or active alcohol drug abuse . 22 . Patient treat betablocker medication screen study . Topical cardioselective betablocker eye medication treatment acute angle glaucoma allow .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>